Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence.
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain.
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.
Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b.
Genpharm and Genzyme Aubagio ® agreement for the MENA region
[Information processing speed and influential factors in multiple sclerosis].
A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
[Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine].
Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.
MicroRNAs: The Role in Autoimmune Inflammation.
Radiologically isolated syndrome: 5-year risk for an initial clinical event.
FDA approves Genzyme’s AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing multiple sclerosis
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis.
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis
Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder.
Mechanism of action for leflunomide in rheumatoid arthritis.
Glial cells as drug targets: What does it take?
Regulation of B cell function by the immunosuppressive agent leflunomide.
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the need.
Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate.
Demyelination induces transport of ribosome-containing vesicles from glia to axons: evidence from animal models and MS patient brains.

Pages